vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Innovex International, Inc. (INVX). Click either name above to swap in a different company.
Innovex International, Inc. is the larger business by last-quarter revenue ($273.6M vs $168.4M, roughly 1.6× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 9.1%). Over the past eight quarters, Innovex International, Inc.'s revenue compounded faster (46.2% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
ESPR vs INVX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $273.6M |
| Net Profit | — | $14.0M |
| Gross Margin | — | 28.9% |
| Operating Margin | 50.6% | 9.4% |
| Net Margin | — | 5.1% |
| Revenue YoY | 143.7% | 9.1% |
| Net Profit YoY | — | -56.1% |
| EPS (diluted) | $0.32 | $0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $273.6M | ||
| Q3 25 | $87.3M | $240.0M | ||
| Q2 25 | $82.4M | $224.2M | ||
| Q1 25 | $65.0M | $240.4M | ||
| Q4 24 | $69.1M | $250.7M | ||
| Q3 24 | $51.6M | $151.8M | ||
| Q2 24 | $73.8M | $130.3M | ||
| Q1 24 | $137.7M | $128.0M |
| Q4 25 | — | $14.0M | ||
| Q3 25 | $-31.3M | $39.2M | ||
| Q2 25 | $-12.7M | $15.3M | ||
| Q1 25 | $-40.5M | $14.8M | ||
| Q4 24 | — | $31.8M | ||
| Q3 24 | $-29.5M | $82.6M | ||
| Q2 24 | $-61.9M | $9.5M | ||
| Q1 24 | $61.0M | $16.4M |
| Q4 25 | — | 28.9% | ||
| Q3 25 | — | 31.6% | ||
| Q2 25 | — | 32.0% | ||
| Q1 25 | — | 31.8% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | — | 34.7% | ||
| Q2 24 | — | 35.3% | ||
| Q1 24 | — | 38.4% |
| Q4 25 | 50.6% | 9.4% | ||
| Q3 25 | -11.4% | 26.0% | ||
| Q2 25 | 8.6% | 10.1% | ||
| Q1 25 | -34.0% | 9.1% | ||
| Q4 24 | -6.4% | 10.7% | ||
| Q3 24 | -31.0% | -8.7% | ||
| Q2 24 | 3.5% | 10.0% | ||
| Q1 24 | 52.5% | 17.4% |
| Q4 25 | — | 5.1% | ||
| Q3 25 | -35.9% | 16.3% | ||
| Q2 25 | -15.4% | 6.8% | ||
| Q1 25 | -62.2% | 6.1% | ||
| Q4 24 | — | 12.7% | ||
| Q3 24 | -57.2% | 54.4% | ||
| Q2 24 | -83.9% | 7.3% | ||
| Q1 24 | 44.3% | 12.8% |
| Q4 25 | $0.32 | $0.20 | ||
| Q3 25 | $-0.16 | $0.57 | ||
| Q2 25 | $-0.06 | $0.22 | ||
| Q1 25 | $-0.21 | $0.21 | ||
| Q4 24 | $-0.14 | $-0.03 | ||
| Q3 24 | $-0.15 | $1.99 | ||
| Q2 24 | $-0.33 | $0.30 | ||
| Q1 24 | $0.34 | $0.51 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | — |
| Total DebtLower is stronger | — | $18.9M |
| Stockholders' EquityBook value | $-302.0M | $1.1B |
| Total Assets | $465.9M | $1.3B |
| Debt / EquityLower = less leverage | — | 0.02× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $86.1M | — | ||
| Q1 25 | $114.6M | — | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | — | ||
| Q2 24 | $189.3M | $185.6M | ||
| Q1 24 | $226.6M | $202.2M |
| Q4 25 | — | $18.9M | ||
| Q3 25 | — | $20.1M | ||
| Q2 25 | — | $34.8M | ||
| Q1 25 | — | $19.7M | ||
| Q4 24 | — | $24.9M | ||
| Q3 24 | — | $12.4M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-302.0M | $1.1B | ||
| Q3 25 | $-451.4M | $1.0B | ||
| Q2 25 | $-433.5M | $995.6M | ||
| Q1 25 | $-426.2M | $978.4M | ||
| Q4 24 | $-388.7M | $958.2M | ||
| Q3 24 | $-370.2M | $904.4M | ||
| Q2 24 | $-344.2M | $352.5M | ||
| Q1 24 | $-294.3M | $344.3M |
| Q4 25 | $465.9M | $1.3B | ||
| Q3 25 | $364.0M | $1.3B | ||
| Q2 25 | $347.1M | $1.2B | ||
| Q1 25 | $324.0M | $1.2B | ||
| Q4 24 | $343.8M | $1.2B | ||
| Q3 24 | $314.1M | $1.1B | ||
| Q2 24 | $352.3M | $1.0B | ||
| Q1 24 | $373.1M | $1.0B |
| Q4 25 | — | 0.02× | ||
| Q3 25 | — | 0.02× | ||
| Q2 25 | — | 0.03× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.03× | ||
| Q3 24 | — | 0.01× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $52.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 3.74× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $52.2M | ||
| Q3 25 | $-4.3M | $48.4M | ||
| Q2 25 | $-31.4M | $59.2M | ||
| Q1 25 | $-22.6M | $31.1M | ||
| Q4 24 | $-35.0M | $36.3M | ||
| Q3 24 | $-35.3M | $21.7M | ||
| Q2 24 | $-7.2M | $22.8M | ||
| Q1 24 | $53.8M | $12.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $-7.3M | $16.6M | ||
| Q1 24 | $53.8M | $7.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | — | ||
| Q2 24 | -9.9% | 12.7% | ||
| Q1 24 | 39.0% | 6.1% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.1% | 4.7% | ||
| Q1 24 | 0.1% | 3.7% |
| Q4 25 | — | 3.74× | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 3.86× | ||
| Q1 25 | — | 2.11× | ||
| Q4 24 | — | 1.14× | ||
| Q3 24 | — | 0.26× | ||
| Q2 24 | — | 2.39× | ||
| Q1 24 | 0.88× | 0.77× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
INVX
| Products | $202.7M | 74% |
| Leasing | $42.3M | 15% |
| Services | $28.6M | 10% |
